FindTrial
Sign In

A study comparing two treatment methods ,one using medicated creams and the other using ultraviolet light therapy for treating a fungal infection causing discoloured skin patches (pityriasis versicolor).

A comparative study on efficacy of topical 2 percent ketoconazole lotion with 0.1 percent adapalene gel versus topical 2 percent ketoconazole lotion with handheld narrowband ultraviolet B therapy in treatment of pityriasis versicolor: A randomized controlled study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099062
Enrollment
84
Registered
2025-12-15
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B360- Pityriasis versicolor

Interventions

Intervention1: Topical 2 percent ketoconazole lotion with 0.1 percent adapalene gel: Participants in group A will include patients of pityriasis versicolor, treated with topical application of ketocon

Sponsors

DR VARSHA V
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients clinically diagnosed with pityriasis versicolor,Patients above fifteen years,Patients willing to provide written informed consent or assent for minors

Exclusion criteria

Exclusion criteria: Pregnant or lactating women. History of chronic liver disease, renal impairment, or immunosuppressive conditions (e.g., HIV/AIDS, organ transplant). Patients currently on immunosuppressive or systemic corticosteroid therapy. Patients who have used any topical or systemic antifungal/retinoid treatment for at least 3 months prior to enrolment. Patients with known allergy or hypersensitivity to ketoconazole, adapalene, or any components of the formulations used. History of photosensitivity disorders or conditions aggravated by UV exposure (e.g., lupus erythematosus, porphyria). Patients who have received phototherapy (e.g., NBUVB, PUVA) in the past 3 months. Patients who are not willing to participate in the study.

Design outcomes

Primary

MeasureTime frame
1. Clinical improvement based on Pityriasis Versicolor Severity Score (pruritus, scaling, pigmentation) using a 0 9 grading scale. 2. Mycological cure confirmed by KOH mount (negative for hyphae/spores). 3. Treatment response assessed using Global Physician Assessment (GPA) scale.Timepoint: outcome will be assessed at baseline (0 week), 4weeks and 8 weeks—

Secondary

MeasureTime frame
Post-treatment adverse effects (erythema, burning, dryness, itching, edema). Patient satisfaction using Likert scale. Photographic assessment evaluated by an independent blinded observer.Timepoint: 1. At each visit Week 0, Week 4, Week 8—

Countries

India

Contacts

Public ContactDR VARSHA V

Sri Devaraj Urs Medical college,Tamaka,Kolar

sbmurugesh@hotmail.com9880399499

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026